Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol.
We report the first case in the world literature of a patient with an atrial septal defect, severe pulmonary hypertension, and equalization of pulmonary and systemic pressures, who underwent successful closure of an ASD following prolonged therapy with the intravenous vasodilator epoprostenol. Judicious use of continuous prostacyclin in apparently inoperable patients with congenital heart disease may be associated with significant reversal of pulmonary hypertension, and conversion to an operable state.
Frost
Adaani E
AE
Baylor College of Medicine, The Methodist Hospital, Houston, Texas 77030, USA. frost@bcm.tmc.edu
Quiñones
Miguel A
MA
Zoghbi
William A
WA
Noon
George P
GP
D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D006328:Cardiac Catheterization; D002302:Cardiac Output / Q000502:physiology; D006348:Cardiac Surgical Procedures; D017548:Echocardiography, Transesophageal; D011464:Epoprostenol / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006344:Heart Septal Defects, Atrial / Q000150:complications / Q000175:diagnosis / Q000601:surgery*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D007262:Infusions, Intravenous; D019990:Perioperative Care; D011669:Pulmonary Wedge Pressure / Q000187:drug effects / Q000502:physiology; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D011464:Epoprostenol